Om Nexium®

Det finns ett oerhört stort antal publikationer om Nexium® (esomeprazol) och nedan nämns endast de viktigaste. Du kan söka efter ett visst ämne eller en författare genom att använda sökfunktionen i sidhuvudet.

Syrakontroll med Nexium® (esomeprazol)

• Wilder-Smith C, Lind T, Lundin C, et al.
  Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007; 42(2): 157–164.
  
• Goldstein J, Miner PB, Schlesinger PK, Liu S, Silberg DG.
  Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006;23:1189–96.
  
• Miner P, Katz P, Chen Y, Sostek M.
  Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a 5-way cross-over study. Am J Gastroenterol 2003;98:2616–20.
  
• Rohss K, Lind T, Wilder-Smith C.
  Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004;60:531–9.
   

Nexium® (esomeprazol) vid refluxsjukdom

• Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83.
  
• Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J et al.
  Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100:1914–22.
  
• Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739–46.
  
• Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22:803–11.
  
• Lauritsen K, Devière J, Bigard M-A, Bayerdörffer E, Mózsik G, Murray F et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003;17:333–41.
  
• Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C et al.
  Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–65.
  
• Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001;15:347–54.
  
• Talley NJ, Venables TL, Green JR, Armstrong D, O’Kane KP, Giaffer M et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857–63.
  

Nexium® (esomeprazol) hos användare av NSAID

• Hawkey CJ, Talley NJ, Scheiman JM, et al.
  Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007; 9: R17 (doi: 10.1186/ar2124
  
• Goldstein JL, Johanson JF, Suchower LJ, Brown MD.
  Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continue to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005;100:2650–7.
  
• Hawkey CJ, Talley NJ, Yeomans ND, Jones R, Sung JJ, Längström G et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including COX-2 inhibitors. Am J Gastroenterol 2005;100:1028–36.
  
• Scheiman JM, Yeomans ND, Talley NJ, Vakil NB, Chan FK, Tulassay Z. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701–10.
  
• Hawkey CJ, Jones RH, Yeomans ND, et al.
  Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007; in press.

Nexium® (esomeprazol) vid H. pylori-associerad peptisk ulcussjukdom

• Tulassay Z, Kryszewski A, Dite P, Kleckowski D, Rudzinski J, Bartuzi Z et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001:13:1457–1465.
  
• Veldhuyzen van Zanten S, Lauritsen K, Delchier J-C, Labenz J, de Argila CM, Lind T et al.
  One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease Aliment Pharmacol Ther 2000;14:1605–1611.